Horizon Therapeutics Public Limited (NASDAQ:HZNP) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totalling 5,130,000 shares, an increase of 19.9% from the October 15th total of 4,280,000 shares. Based on an average trading volume of 2,070,000 shares, the days-to-cover ratio is currently 2.5 days.
Horizon Therapeutics Public stock traded down $0.94 during midday trading on Friday, reaching $70.15. The stock had a trading volume of 2,432,001 shares, compared to its average volume of 2,238,720. The stock has a market capitalization of $15.48 billion, a P/E ratio of 19.17, a price-to-earnings-growth ratio of 0.95 and a beta of 1.32. The firm’s fifty day simple moving average is $77.13 and its 200-day simple moving average is $64.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.45 and a current ratio of 3.49. Horizon Therapeutics Public has a 1-year low of $23.81 and a 1-year high of $86.67.
Horizon Therapeutics Public (NASDAQ:HZNP) last issued its quarterly earnings results on Saturday, November 7th. The biopharmaceutical company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.77. Horizon Therapeutics Public had a net margin of 43.55% and a return on equity of 25.66%. The company had revenue of $636.40 million during the quarter, compared to analysts’ expectations of $531.11 million. During the same period last year, the business earned $0.64 EPS. The business’s quarterly revenue was up 89.4% on a year-over-year basis. On average, sell-side analysts anticipate that Horizon Therapeutics Public will post 3.19 earnings per share for the current fiscal year.
In other Horizon Therapeutics Public news, SVP Miles W. Mchugh sold 12,124 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $75.48, for a total transaction of $915,119.52. Following the transaction, the senior vice president now owns 21,597 shares in the company, valued at $1,630,141.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Paul W. Hoelscher sold 29,576 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $75.76, for a total value of $2,240,677.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,063 shares of company stock worth $7,912,687. Insiders own 4.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Congress Asset Management Co. MA increased its position in shares of Horizon Therapeutics Public by 723.0% in the second quarter. Congress Asset Management Co. MA now owns 1,955,384 shares of the biopharmaceutical company’s stock valued at $108,680,000 after acquiring an additional 1,717,803 shares during the last quarter. FMR LLC raised its stake in shares of Horizon Therapeutics Public by 22.1% during the 2nd quarter. FMR LLC now owns 7,288,468 shares of the biopharmaceutical company’s stock worth $405,093,000 after purchasing an additional 1,317,555 shares in the last quarter. Allianz Asset Management GmbH raised its stake in shares of Horizon Therapeutics Public by 51.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,676,798 shares of the biopharmaceutical company’s stock worth $285,614,000 after purchasing an additional 1,249,989 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Horizon Therapeutics Public by 81.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,007,625 shares of the biopharmaceutical company’s stock valued at $111,583,000 after buying an additional 900,544 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new position in Horizon Therapeutics Public during the second quarter worth $46,167,000. Hedge funds and other institutional investors own 89.17% of the company’s stock.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: Green Investing
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.